BioBusiness

Chris Spivey is the editorial director of 

Videos

During Bio 2024, Aaron Cowley, PhD, chief technical officer and co-founder, Captozyme, discussed the advancement in development of microbiome-derived therapeutics.

Development and Manufacturing Advances for Microbiome-Derived Therapeutics (BIO 2024)

Feliza Mirasol is the science editor for 

Articles

Under a deal worth potentially up to $1.3 billion, Merck, known as MSD outside of the United States and Canada, will acquire CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical. 

Merck Plans to Acquire Investigational Bispecific Antibody from Curon Biopharmaceutical in $1.3 Billion Deal

Genentech will leverage Sangamo’s proprietary capsid delivery platform and epigenetic regulation capabilities to develop genomic medicines to address certain neurodegenerative diseases.

Genentech Licenses Sangamo Therapeutics’ Epigenetic Regulation and Capsid Technologies in Nearly $2 Billion Deal for Genomics Medicines

 is Industry Market Manager Biopharma, Pharma EMEA - Brenntag GmbH.

Biopharmaceutical production faces the challenge of ensuring the quality of raw materials due to a lack of specific guidelines. By implementing effective risk assessment strategies and working with reliable, selected solution providers, biopharmaceutical manufacturers can minimize these challenges and improve product quality.

The Quest for Quality: Challenges and Strategies in Raw Material Selection for Biopharmaceuticals

The new biotech company will use the Series A financing to advance the development of enhanced biologics to treat solid tumors and inflammatory and immunology diseases.

Biotech Company, Third Arc Bio, Receives $165 Million in Financing to Advance Biologic Drug Development Pipeline

BeiGene has invested $800 million into a new biologics manufacturing facility in Hopewell, NJ, which also houses its clinical R&D capabilities.

BeiGene Launches Biologics Manufacturing and Clinical R&D Facility in New Jersey

GSK’s submission is supported by Phase III trials showing significant progression-free survival benefit and positive overall survival trends using Blenrep combinations compared to standard care.

EMA Accepts GSK Application for Blenrep Combinations in Multiple Myeloma Treatment

The acquisition adds a Phase III therapeutic peptide candidate to AstraZeneca’s late-stage pipeline for rare diseases.

AstraZeneca Strengthens Rare Disease Portfolio with Amolyt Pharma Acquisition

The acquisition adds NM26, a Phase II-ready bispecific antibody for treating atopic dermatitis, to Johnson & Johnson’s immune-mediated and inflammatory disease portfolio.

Johnson & Johnson Completes Numab Subsidiary Acquisition, Boosts Bispecific Antibody Pipeline

Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.

The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.

Biologic Drugs in Development